• Je něco špatně v tomto záznamu ?

Pregnancy outcomes in women with growth hormone deficiency

G. Vila, AC. Akerblad, AF. Mattsson, M. Riedl, SM. Webb, V. Hána, EH. Nielsen, BM. Biller, A. Luger,

. 2015 ; 104 (5) : 1210-7.e1. [pub] 20150806

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010009

OBJECTIVE: To study pregnancies in a large group of patients with growth hormone deficiency and hypopituitarism; and to investigate potential factors determining pregnancy outcomes and pregnancy complications. DESIGN: We analyzed pregnancies reported in KIMS, the Pfizer International Metabolic Database, of adult patients with growth hormone deficiency treated with growth hormone. SETTING: Outpatient clinics. PATIENT(S): A total of 201 pregnancies were reported: 173 in female patients and 28 in partners of male patients. INTERVENTION(S): Growth hormone replacement therapy (GHRT) was prescribed according to the local clinical practice. MAIN OUTCOME MEASURE(S): Pregnancy outcomes (live births, gestational week at delivery, and birth weight), pregnancy complications, and their relationship to use of GHRT during pregnancy were analyzed with regression models. RESULT(S): Two-thirds of women underwent fertility treatment to achieve pregnancy. Growth hormone replacement therapy was stopped before pregnancy in 7.5% of the female patients, as soon as pregnancy was confirmed in 40.1%, and at the end of the second trimester in 24.7% of the patients, whereas 27.6% continued GHRT throughout pregnancy. Birth of a healthy child was reported in 79% of the female pregnancies, nonelective abortions occurred mainly in the first trimester, and one fetal malformation (cystic hygroma) was diagnosed in the second trimester. Pregnancy outcomes and pregnancy complications were not related to GHRT treatment patterns, method of conception, or number of additional pituitary deficiencies. CONCLUSION(S): These data on pregnancy outcomes in a large group of women with hypopituitarism revealed no relationship between GHRT regimens and pregnancy outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010009
003      
CZ-PrNML
005      
20160413113854.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.fertnstert.2015.07.1132 $2 doi
024    7_
$a 10.1016/j.fertnstert.2015.07.1132 $2 doi
035    __
$a (PubMed)26256649
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vila, Greisa $u Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: greisa.vila@meduniwien.ac.at.
245    10
$a Pregnancy outcomes in women with growth hormone deficiency / $c G. Vila, AC. Akerblad, AF. Mattsson, M. Riedl, SM. Webb, V. Hána, EH. Nielsen, BM. Biller, A. Luger,
520    9_
$a OBJECTIVE: To study pregnancies in a large group of patients with growth hormone deficiency and hypopituitarism; and to investigate potential factors determining pregnancy outcomes and pregnancy complications. DESIGN: We analyzed pregnancies reported in KIMS, the Pfizer International Metabolic Database, of adult patients with growth hormone deficiency treated with growth hormone. SETTING: Outpatient clinics. PATIENT(S): A total of 201 pregnancies were reported: 173 in female patients and 28 in partners of male patients. INTERVENTION(S): Growth hormone replacement therapy (GHRT) was prescribed according to the local clinical practice. MAIN OUTCOME MEASURE(S): Pregnancy outcomes (live births, gestational week at delivery, and birth weight), pregnancy complications, and their relationship to use of GHRT during pregnancy were analyzed with regression models. RESULT(S): Two-thirds of women underwent fertility treatment to achieve pregnancy. Growth hormone replacement therapy was stopped before pregnancy in 7.5% of the female patients, as soon as pregnancy was confirmed in 40.1%, and at the end of the second trimester in 24.7% of the patients, whereas 27.6% continued GHRT throughout pregnancy. Birth of a healthy child was reported in 79% of the female pregnancies, nonelective abortions occurred mainly in the first trimester, and one fetal malformation (cystic hygroma) was diagnosed in the second trimester. Pregnancy outcomes and pregnancy complications were not related to GHRT treatment patterns, method of conception, or number of additional pituitary deficiencies. CONCLUSION(S): These data on pregnancy outcomes in a large group of women with hypopituitarism revealed no relationship between GHRT regimens and pregnancy outcomes.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a porodní hmotnost $7 D001724
650    _2
$a faktografické databáze $7 D016208
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gestační stáří $7 D005865
650    _2
$a hormonální substituční terapie $x škodlivé účinky $7 D020249
650    _2
$a lidský růstový hormon $x aplikace a dávkování $x škodlivé účinky $x krev $x nedostatek $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a hypopituitarismus $x krev $x komplikace $x diagnóza $x farmakoterapie $7 D007018
650    _2
$a narození živého dítěte $7 D050498
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a těhotenství $7 D011247
650    _2
$a komplikace těhotenství $x etiologie $7 D011248
650    12
$a výsledek těhotenství $7 D011256
650    _2
$a prospektivní studie $7 D011446
650    _2
$a asistovaná reprodukce $7 D027724
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Akerblad, Ann-Charlotte $u Pfizer Endocrine Care, Sollentuna, Sweden. $7 gn_A_00002873
700    1_
$a Mattsson, Anders F $u Pfizer Endocrine Care, Sollentuna, Sweden.
700    1_
$a Riedl, Michaela $u Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
700    1_
$a Webb, Susan M $u IIB-Sant Pau and Service of Endocrinology, Department of Medicine, Centro de Investigación Biomédica en Enfermedades Raras (CIBER-ER Unidad 747), Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
700    1_
$a Hána, Václav $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Nielsen, Eigil H $u Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
700    1_
$a Biller, Beverly M K $u Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
700    1_
$a Luger, Anton $u Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
773    0_
$w MED00001795 $t Fertility and sterility $x 1556-5653 $g Roč. 104, č. 5 (2015), s. 1210-7.e1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26256649 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160413113938 $b ABA008
999    __
$a ok $b bmc $g 1113438 $s 934377
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 104 $c 5 $d 1210-7.e1 $e 20150806 $i 1556-5653 $m Fertility and sterility $n Fertil Steril $x MED00001795
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace